ASH 2023 | Impact of dex dose reduction on outcomes in newly diagnosed multiple myeloma
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, outlines the findings of a secondary analysis of SWOG studies S0777 (NCT00644228) and S1211 (NCT01668719), which aimed to understand the impact dexamethasone (dex) dose reduction during the induction period has on post-induction outcomes in patients with newly diagnosed multiple myeloma (NDMM). Although there were some limitations to the post hoc analysis, dex dose reductions during induction were not found to impact post-induction progression-free survival (PFS) or overall survival (OS), even in patients where significant dose reduction was necessary for various reasons. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: SparkCures, Janssen, BMS, Genentech, Sanofi, Caribou, Pfizer
Research Funding: Pack Health
